What Aldurazyme contains
- The active substance is laronidase. One ml of the solution in the vial contains 100 U of laronidase. Each vial of 5 ml contains 500 U of laronidase.
- The other ingredients are: Sodium chloride, Sodium phosphate monobasic monohydrate, Sodium phosphate dibasic heptahydrate, Polysorbate 80, Water for injections
What Aldurazyme looks like and contents of the pack
Aldurazyme is supplied as a concentrate for solution for infusion. It is a solution that is clear to slightly opalescent, and colourless to pale yellow.
Pack size: 1, 10 and 25 vials per carton. Not all pack sizes may be marketed.
Marketing Authorisation Holder
Genzyme Europe B.V., Gooimeer 10, NL-1411 DD, Naarden, The Netherlands.
Manufacturer
Genzyme Ltd., 37 Hollands Road, Haverhill, Suffolk CB9 8PU, United Kingdom.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Magyarország Genzyme Europe B.V. Képviselet, Tel 36 1 310 7440 BelgiëBelgiqueBelgien Luxemburg Luxembourg Genzyme Belgium N.V., TélTel 32 2 714 17 11
Nederland Genzyme Europe B.V., Tel 31 35 6991200 Genzyme CEE GmbH . 359 2 971 1001
Österreich Genzyme Austria GmbH, Tel 43 1 774 65 38 eská republikaSlovenská RepublikaSlovenija Genzyme Czech, s.r.o., Tel 420 227 133 665
DanmarkNorgeSverigeSuomiFinland Ísland Genzyme AS, DanmarkTanskaDanmörk, TlfPuh.Sími 45 32712600 PolskaEestiLatvijaLietuva Genzyme Polska Sp. z o.o. PoolaPolijaLenkija, Tel 48 22 24 60 900
Deutschland Genzyme GmbH, Tel 49 610236740 Portugal Genzyme Portugal S.A., Tel 351 21 422 0100
Genzyme Hellas Ltd. 30 210 99 49 270 România Genzyme CEE GmbH- Reprezentana pentru România Tel 40 21 243 42 28
España Genzyme, S.A., Tel 34 91 6591670 United KingdomIreland Genzyme Therapeutics Ltd. United Kingdom Tel 44 1865 405200
France
Genzyme S.A.S.,
Tél: + 33 (0) 825 825 863
Italia/Malta
Genzyme Srl (Italia/Italja),
Tel: +39 059 349811
This leaflet was last approved in
This medicine has been authorised under ?exceptional circumstances?.
This means that because of the rarity of this disease it has been impossible to get complete information on this medicine.
The European Medicines Agency (EMEA) will review any new information on the medicine every year and this leaflet will be updated as necessary.
<-------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only:
Each vial of Aldurazyme is intended for single use only. The concentrate for solution for infusion has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion using aseptic technique. It is recommended that the diluted Aldurazyme solution be administered to patients using an infusion set equipped with an 0.2 µm in-line filter.
From a microbiological safety point of view, the product should be used immediately. If not used immediately, in-use storage should not be longer than 24 hours at 2°C - 8°C provided that dilution has taken place under controlled and validated aseptic conditions.
Aldurazyme should not be mixed with other medicinal products in the same infusion.
Preparation of the Aldurazyme Infusion (Use Aseptic Technique)
Determine the number of vials to be diluted based on the individual patient's weight. Remove the required vials from the refrigerator approximately 20 minutes in advance in order to allow them to reach room temperature (below 30-C).
Before dilution, visually inspect each vial for particulate matter and discoloration. The clear to slightly opalescent and colourless to pale yellow solution should be free of visible particles. Do not use vials exhibiting particles or discoloration.
Determine the total volume of infusion based on the individual patient's weight, either 100 ml (if bodyweight is less or equal than 20 kg) or 250 ml (if bodyweight is more than 20 kg) of 0.9% sodium chloride intravenous solution.
Withdraw and discard a volume of sodium chloride 9 mg/ml (0.9%) solution for infusion from the infusion bag equal to the total volume of Aldurazyme to be added.
Withdraw the required volume from the Aldurazyme vials and combine the withdrawn volumes. Add the combined volumes of Aldurazyme to the sodium chloride 9 mg/ml (0.9%) solution for infusion.
Mix the solution for infusion gently.
Prior to use visually inspect the solution for particulate matter. Only clear and colourless solutions without visible particles should be used.
Any unused product or waste material should be disposed of in accordance with local requirements.